Home › Cervical Cancer › California › Los Angeles
Cervical Cancer clinical trials in Los Angeles, CA
16 studies for Cervical Cancer are looking for participants at sites in and around Los Angeles (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RecruitingPhase 1
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RecruitingPhase 1/2
- University of Southern California, Los Angeles
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecruitingPhase 1
- START - Los Angeles, Los Angeles
- Cedars Sinai, Los Angeles
Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers
Recruiting
- University of California at Los Angeles, Los Angeles
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- USC/Norris Comprehensive Cancer Center, Los Angeles
A Study of MGC026 in Participants With Advanced Solid Tumors
RecruitingPhase 1
- The Angeles Clinic and Research Institute, Los Angeles
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
RecruitingPhase 1/2
- Los Angeles Cancer Network, Los Angeles
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
Recruiting
- UCLA Gynecologic Oncology Clinic, Los Angeles
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
RecruitingPhase 1
- START Los Angeles, Los Angeles
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- Ellison Clinic at Saint John's, Los Angeles
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RecruitingPhase 1
- Ronald Reagan UCLA Medical Center, Los Angeles
- The Regents of the University of California, Los Angeles
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
A Study of VET3-TGI in Patients With Solid Tumors
RecruitingPhase 1
- USC/Norris Comprehensive Cancer Center, Los Angeles
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RecruitingPhase 1/2
- University of Southern California, Los Angeles
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RecruitingPhase 1/2
- Research Site 125, Los Angeles
- Research Site 133, Los Angeles
- Research Site 103, Los Angeles
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
RecruitingPhase 1/2
- Cedars Sinai Medical Center, Los Angeles
A Study of NX-1607 in Adults With Advanced Malignancies
RecruitingPhase 1
- University of Southern California, Los Angeles
About Cervical Cancer
Cervical cancer starts in the cells of the cervix, which is the lower, narrow end of the uterus. Long-lasting HPV infection causes almost all cervical cancers.
More about Cervical Cancer on MedlinePlus
Cervical Cancer trials in other cities
- Houston, TX34 studies
- New York City, NY19 studies
- Nashville, TN19 studies
- Boston, MA18 studies
- Arlington, VA16 studies
- San Antonio, TX14 studies
- St. Louis, MO13 studies
- Dallas, TX13 studies
- Orlando, FL12 studies
- Chicago, IL12 studies
- Columbus, OH11 studies
- Atlanta, GA11 studies
Other studies in Los Angeles
- Non-Small Cell Lung Cancer87 studies
- Cancer (all types)74 studies
- Breast Cancer73 studies
- Prostate Cancer61 studies
- Colorectal Cancer59 studies
- Metastatic Cancer57 studies
- Ovarian Cancer50 studies
- Lung Cancer45 studies
- Head and Neck Squamous Cell Carcinoma42 studies
- Pancreatic Cancer35 studies
- Endometrial Cancer34 studies
- Melanoma34 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.